For treating moderately to severely active ulcerative colitis - Nice TA856
MHRA Drug Safety Update, 26 April 2023
1.1 Upadacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults:
- when conventional or biological treatment cannot be tolerated, or
- if the condition has not responded well enough or has stopped responding to these treatments, and
- if the company provides upadacitinib according to the commercial arrangement.